Multiple sclerosis vaccine - Pharmasynthez

Drug Profile

Multiple sclerosis vaccine - Pharmasynthez

Alternative Names: Xemys

Latest Information Update: 14 Apr 2016

Price : $50

At a glance

  • Originator Pharmasyntez
  • Class Oligopeptides; Peptide vaccines; Vaccines
  • Mechanism of Action CD antigen modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple sclerosis

Most Recent Events

  • 01 Apr 2016 Phase-II clinical trials in Multiple sclerosis (Recurrent, Treatment-experienced) in Russia (SC) (before April 2016)
  • 01 Apr 2016 Safety and efficacy data from a phase IIa trial in Multiple sclerosis (Recurrent, Treatment-experienced) released by Pharmasynthez
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top